期刊
INTERNATIONAL JOURNAL FOR PARASITOLOGY
卷 38, 期 7, 页码 791-798出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.ijpara.2007.12.002
关键词
Plasmodium falciparum; in vitro; Mali; pLDH ELISA; isotopic; drug resistance
类别
资金
- Howard Hughes Medical Institute [55005502] Funding Source: Medline
- NIAID NIH HHS [5R01 AI 44824-03, R01 AI044824] Funding Source: Medline
In vitro susceptibility to antimalarial drugs of Malian Plasmodium falciparum isolates collected between 2004 and 2006 was studied. Susceptibility to chloroquine and to three artemisinin-based combination therapy (ACT) component drugs was assessed as a first, to our knowledge, in vitro susceptibility study in Mali. Overall 96 Malian isolates (51 from around Bamako and 45 collected from French travellers returning from Mali) were cultivated in a CO2 incubator. Fifty percent inhibitory concentrations IC50S) were measured by either hypoxanthine incorporation or Plasmodium lactate dehydrogenase (pLDH) ELISA. Although the two sets of data were generated with different methods, the global IC50 distributions showed parallel trends. A good concordance of resistance phenotype with pfcrt 76T mutant genotype was found within the sets of clinical isolates tested. We confirm a high prevalence of P. falciparum in vitro resistance to chloroquine in Mali (60-69%). While some isolates showed IC(50)s Close to the cut-off for resistance to monodesethylamodiaquine, no decreased susceptibility to dihydroartemisinin or lumefantrine was detected. This study provides baseline data for P. falciparum in vitro susceptibility to ACT component drugs in Mali. (C) 2007 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据